ENTA - CIK 0001177648
ENANTA PHARMACEUTICALS INC (ENTA) reported net income of -$81.89M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$81.89M | +29.4% |
| FY 2024 | -$116.05M | +13.3% |
| FY 2023 | -$133.82M | -9.9% |
| FY 2022 | -$121.75M | -54.1% |
| FY 2021 | -$79.00M | -118.4% |
| FY 2020 | -$36.17M | -178.0% |
| FY 2019 | $46.38M | -35.5% |
| FY 2018 | $71.96M | +306.3% |
| FY 2017 |
ENANTA PHARMACEUTICALS INC (ENTA) reported net income of -$81.89M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ENANTA PHARMACEUTICALS INC's net income declined from $23.31M to -$81.89M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $17.71M |
| -18.3% |
| FY 2016 | $21.67M | -72.6% |
| FY 2015 | $78.99M | +129.4% |
| FY 2014 | $34.44M | +257.7% |
| FY 2013 | $9.63M | -55.0% |
| FY 2012 | $21.40M | -8.2% |
| FY 2011 | $23.31M | - |